Pediatric Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, and Other Drug Types), Route of Administration (Oral, Topical, Parenteral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle-East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Pediatric Drugs Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4.6 %
Pediatric Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The pediatric drugs market was anticipated to witness a CAGR of nearly 4.6% during the forecast period.

The COVID-19 pandemic impacted the global pediatric drug market. In the business world, the COVID-19 pandemic has created unprecedented economic uncertainty. While some businesses are relatively insulated due to low exposure, many others have been unable to avoid the pandemic's effects and are experiencing financial hardship. The COVID-19 pandemic and subsequent public health guidance to reduce the spread of the disease have wide-reaching implications for children's health and wellbeing. Pediatric emergency departments (EDs) have rapidly adapted the provision of care in response to the pandemic.

The major factors attributing to the growth of the pediatric drugs market are a rise in the birth rate compared to previous years and the increased volume of fatal pediatric cases, which are leading to even deaths due to various diseases, viral infections, GI disorders, lung cancers, and malnutrition. According to the United Nations International Children's Emergency Fund (UNICEF) 2020 Report, 5.0 million children under five were expected to die by 2020. In 2020, this translated to 13,800 children under five dying each day. Infectious diseases such as pneumonia, diarrhea, and malaria, and preterm birth and intrapartum complications continue to be the leading causes of death among children under the age of five worldwide. Hence, deaths among children under age five demand efficient treatment. The rise in prevalence of renal or pulmonary dysfunctions following hematopoietic stem-cell transplantations (HSCT) due to defective or low immunity results in the growth of the global pediatric drugs market.

Scope of the Report

Pediatric medicine is a branch of medicine that deals with the medical care, development, and related diseases of infants, children, and adolescents. The pediatric drugs market grows significantly as children often suffer from gastrointestinal, allergic, respiratory, and other chronic diseases due to their lower immunity. The market is segmented by Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, and Other Drug Types), Route of Administration (Oral, Topical, Parenteral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

Drug Type
Respiratory Disorder Drugs
Autoimmune Disorder Drugs
Gastrointestinal Drugs
Cardiovascular Drugs
Other Drug Types
Route of Administration
Other Routes of Administration
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Respiratory Disorder Drugs Segment By Indication is Expected to Hold the Major Market Share in the Pediatric Drugs Market

The respiratory disorder drugs segment is expected to account for the largest share of the pediatric drugs market due to lower immunity, increased pollution, and exposure to various allergens, resulting in chronic respiratory disorders such as Chronic obstructive pulmonary disease (COPD). COPD is a major cause of the global pediatric healthcare burden, leading to an increased demand for the efficient treatment of the diseases, in turn fueling the market. According to the World Health Organization 2021, Chronic Obstructive Pulmonary Disease (COPD) was the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing prevalence of COPD among children is expected to boost the market growth over the forecast period.

On the other hand, the rare autoimmune disorders drugs segment is anticipated to witness the fastest CAGR and dominate the market during the forecast period. The segment's dominance can be attributed to the increased prevalence of these disorders due to rising coincidences among the patients with various cancers, genetic disorders, and other autoimmune disorders, which provides incentives to assist and encourage the development of drugs for rare diseases. For instance, in May 2019, the Jacobus pharmaceutical company received approval from the US Food and Drug Administration (FDA) under Priority Review and Fast Track designations for its RUZURGI (amifampridine) tablets. Ruzurgi also received orphan drug designation for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in pediatric patients. These prescription drugs' high cost may also attribute to the fastest growth, propelling the global pediatric drugs market during the forecast period.

Pediatric Drugs Market Trends

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the pediatric drugs market due to the rise in the volume of pediatric patient cases with kids suffering from various autoimmune disorders, respiratory disorders, cerebral palsy, and muscular atrophy, along with a steep rise in the adoption of advanced technologies in the US, which holds the major revenue share of the market in North America.

For instance, according to the article published in the JAMA Network in 2020 by Luyu Xie, asthma was one of the world's most common chronic diseases in children. In the United States, 6 million children (roughly 8% of the population) have been diagnosed with asthma, costing USD 81.9 billion in annual health care costs and resulting in high demand for pediatric drugs.

The launch of new products by key players in the region for pediatric patients, rise in government initiatives to create awareness in people for pediatric medicines, and early approvals with accelerated drug approval initiative by the USFDA to encourage the development of drugs for rare diseases and to decrease the rising pediatric burden are likely to create more opportunities in the market. For instance, in 2020, Veklury (remdesivir), an antiviral medication, was licensed by the US Food and Drug Administration for use in adults and children aged 12 and above.

Also, the rise in disposable income and improvements in healthcare infrastructure are likely to help the global pediatric healthcare market's growth over the forecast period.

Pediatric Drugs Market Forecast

Competitive Landscape

The pediatric drugs market is moderately competitive and consists of several major players. A few major players are currently dominating the market in terms of market share. Some prominent players are launching new products to address the unmet challenges in the market, while others are distributing the products. For instance, in April 2019, GSK received approval from the US Food and Drug Administration (FDA) for its intravenous (IV) Benlysta (belimumab), the first medicine approved in the US for children with systemic lupus erythematosus (SLE) from as young as five years of age cranial defects. Some companies currently dominating the market include BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., and Jazz Pharmaceuticals Inc.

Recent Developments

  • In December 2021, Novartis announced the US FDA's approval for Cosentyx (secukinumab) in the treatment of active enthesitis-related arthritis (ERA) in four years and older and active juvenile psoriatic arthritis (JPsA) in patients two years and older.
  • In October 2021, the United States Food and Drug Administration (USFDA) approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder. Rethymic is the first thymus tissue product approved in the United States.

Table of Contents


    1. 1.1 Study Assumptions and Market defination

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Pediatric Diseases such as Diabetes, Respiratory Disorders, and Rise in Affordability with Disposable Income

      2. 4.2.2 Increased R&D Activities and Awareness of Pediatric Medicine Among Public

    3. 4.3 Market Restraints

      1. 4.3.1 Small Size of Study Population and Ethical Issues in Pediatric Research

      2. 4.3.2 Risk of Severe Complications Associated with Medicines that may lead to Death

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 Drug Type

      1. 5.1.1 Respiratory Disorder Drugs

      2. 5.1.2 Autoimmune Disorder Drugs

      3. 5.1.3 Gastrointestinal Drugs

      4. 5.1.4 Cardiovascular Drugs

      5. 5.1.5 Other Drug Types

    2. 5.2 Route of Administration

      1. 5.2.1 Oral

      2. 5.2.2 Topical

      3. 5.2.3 Parenteral

      4. 5.2.4 Other Routes of Administration

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 PTC Therapeutics Inc.

      2. 6.1.2 BioMarin Pharmaceutical Inc.

      3. 6.1.3 Horizon Therapeutics PLC

      4. 6.1.4 Sumitomo Dainippon Pharma Co. Ltd

      5. 6.1.5 Gilead Sciences Inc.

      6. 6.1.6 Jazz Pharmaceuticals Inc.

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Glaxosmithkline PLC

      9. 6.1.9 Johnson & Johnson

      10. 6.1.10 Boehringer Ingelheim International GmbH

      11. 6.1.11 Sanofi SA

      12. 6.1.12 Novartis AG

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Pediatric Drugs Market market is studied from 2019 - 2027.

The Global Pediatric Drugs Market is growing at a CAGR of >4.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

BioMarin Pharmaceutical Inc, Horizon Therapeutics plc, Sumitomo Dainippon Pharma Co Ltd, Jazz Pharmaceuticals Inc, Gilead Sciences Inc are the major companies operating in Global Pediatric Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!